Effects of Chebulic Acid on Advanced Glycation Endproducts-Induced Collagen Cross-Links

被引:19
作者
Lee, Ji-young [1 ]
Oh, Jun-Gu [1 ]
Kim, Jin Sook [2 ]
Lee, Kwang-Won [1 ]
机构
[1] Korea Univ, Coll Life Sci & Biotechnol, Dept Food Biosci & Technol, Seoul 136713, South Korea
[2] Korea Inst Oriental Med, Diabet Complicat Res Ctr, Div Tradit Korean Med Integrated Res, Taejon 305811, South Korea
关键词
chebulic acid; Terminalia chebula; chelating activity; collagen cross-link; advanced glycation end-product; antiglycation effect; END-PRODUCTS; TERMINALIA-CHEBULA; AGE INHIBITORS; BREAKERS; ARTERIAL;
D O I
10.1248/bpb.b14-00034
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Advanced glycation end-products (AGEs) have been implicated in the development of diabetic complications. We report the antiglycating activity of chebulic acid (CA), isolated from Terminalia chebula on breaking the cross-links of proteins induced by AGEs and inhibiting the formation of AGEs. Aminoguanidine (AG) reduced 50% of glycated bovine serum albumin (BSA) with glycolaldehyde (glycol-BSA)-induced cross-links of collagen at a concentration of 67.8 +/- 2.5 mM, the level of CA required for exerting a similar antiglycating activity was 38.8 +/- 0.5 mu M. Also, the breaking activity on collagen cross-links induced by glycol-BSA was potent with CA (IC50=1.46 +/- 0.05 mM), exhibiting 50-fold stronger breaking activity than with ALT-711, a well-known cross-link breaker (IC50=72.2 +/- 2.4 mM). IC50 values of DPPH. scavenging activity for CA and ascorbic acid (AA) were 39.2 +/- 4.9 and 19.0 +/- 1.29 mu g dry matter (DM) mL(-1), respectively, and ferric reducing and antioxidant power (FRAP) activities for CA and AA were 4.70 +/- 0.06 and 11.4 +/- 0.1 mmol/FeSO4 center dot 7H(2)O/g DM, respectively. The chelating activities of CA, AG and ALT711 on copper-catalyzed oxidation of AA were compared, and in increasing order, ALT-711 (IC50 of 1.92 +/- 0.20 mM)<CA (IC50 of 0.96 +/- 0.07 mM)<AG (0.47 +/- 0.05 mM). Thus, CA could be a breaker as well as an inhibitor of AGE cross-linking, the activity of which may be explained in large part by its chelating and antioxidant activities, suggesting that CA may constitute a promising antiglycating candidate in intervening AGE-mediated diabetic complications.
引用
收藏
页码:1162 / 1167
页数:6
相关论文
共 25 条
[1]   Screening of some Indian medicinal plants for their antimicrobial properties [J].
Ahmad, I ;
Mehmood, Z ;
Mohammad, F .
JOURNAL OF ETHNOPHARMACOLOGY, 1998, 62 (02) :183-193
[2]   Advanced glycation endproducts - role in pathology of diabetic complications [J].
Ahmed, N .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2005, 67 (01) :3-21
[3]   AMINOGUANIDINE PREVENTS DIABETES-INDUCED ARTERIAL-WALL PROTEIN CROSS-LINKING [J].
BROWNLEE, M ;
VLASSARA, H ;
KOONEY, A ;
ULRICH, P ;
CERAMI, A .
SCIENCE, 1986, 232 (4758) :1629-1632
[4]  
BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315
[5]  
Bucala CA, 1992, ADV GLYCOSYLATION CH
[6]  
Cerami A, 2001, Novartis Found Symp, V235, P202
[7]  
Cerami A, 2001, NOVART FDN SYMP, V235
[8]   The role of advanced glycation end products in progression and complications of diabetes [J].
Goh, Su-Yen ;
Cooper, Mark E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (04) :1143-1152
[9]   Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure [J].
Hartog, Jasper W. L. ;
Willemsen, Suzan ;
van Veldhuisen, Dirk J. ;
Posma, Jan L. ;
van Wijk, Leen M. ;
Hummel, Yoran M. ;
Hillege, Hans L. ;
Voors, Adriaan A. .
EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (08) :899-908
[10]  
Kim YS, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI DOI 10.1371/J0URNAL.P0NE.0024621